BioAdvance News Portfolio News Relmada Therapeutics

Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder

By WebmasterOctober 13, 2022November 1st, 2024No Comments

Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder

See more here

Previous PostPhiladelphia medtech company Bainbridge Health raises $3.35M
Next PostAnnovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease

Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostPhiladelphia medtech company Bainbridge Health raises $3.35M

Next PostAnnovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease